Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002405 · ClinicalTrials.gov registry record · NA
A Study of Amprenavir in HIV-Infected Patients
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002405 is a NA study that has completed, run by Glaxo Wellcome.
The verdict
NCT00002405, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The purpose of this study is to see if it is safe to give amprenavir (APV) to HIV-infected patients. This study also examines the effect APV has on the level of HIV in the blood. Earlier studies have shown that APV is effective in slowing the growth of HIV in the body. Patients who have failed previous anti-HIV treatment or who are unable to take other protease inhibitors (PIs) may benefit from the availability of a new PI such as APV.
Interventions
- DRUG Amprenavir
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002405
The ClinicalTrials.gov registry entry for NCT00002405 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amprenavir is the first listed.
NCT00002405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002405 about?
NCT00002405 is a clinical study titled "A Study of Amprenavir in HIV-Infected Patients". The purpose of this study is to see if it is safe to give amprenavir (APV) to HIV-infected patients. This study also examines the effect APV has on the level of HIV in the blood. Earlier studies have shown that APV is effective in slowing the growth of HIV in the body. Patients who have failed prev...
What is the current status of trial NCT00002405?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002405?
The interventions under investigation include: Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00002405?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.